Cardiovascular Systems, Inc. (CSII)
(Delayed Data from NSDQ)
$39.49 USD
+1.98 (5.28%)
Updated May 3, 2019 04:00 PM ET
After-Market: $39.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$39.49 USD
+1.98 (5.28%)
Updated May 3, 2019 04:00 PM ET
After-Market: $39.52 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Cardiovascular Systems' (CSII) Q2 Earnings Lag Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) exhibits a robust performance by its worldwide coronary franchise despite challenging business climate.
Cardiovascular Systems (CSII) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -64.29% and 5.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cardiovascular Systems (CSII) Expands Lithotripsy Technology
by Zacks Equity Research
Cardiovascular Systems (CSII) has developed intravascular lithotripsy systems to treat calcific coronary and peripheral artery diseases.
Cardiovascular Systems (CSII) Coronary Sales Up Amid COVID Woe
by Zacks Equity Research
Cardiovascular Systems (CSII) continues to experience strong demand for physician training and certification in all international markets.
New Strong Sell Stocks for December 28th
by Zacks Equity Research
DVA, CSII, BYND, AVYA, and GFF have been added to the Zacks Rank #5 (Strong Sell) List on December 28, 2021.
New Strong Sell Stocks for December 3rd
by Zacks Equity Research
CSII, KELYA, LL, ATHM, and BLMN have been added to the Zacks Rank #5 (Strong Sell) List on December 3, 2021
New Strong Sell Stocks for November 19th
by Zacks Equity Research
AMED, CSII, DVA, GFF, and LTRX have been added to the Zacks Rank #5 (Strong Sell) List on November 19, 2021.
Cardiovascular Systems (CSII) Business Down on COVID Resurgence
by Zacks Equity Research
According to Cardiovascular Systems (CSII), the resurgence of COVID-19 and the related staffing shortages are disrupting referral patterns and having the largest impact on elective procedures.
New Strong Sell Stocks for November 12th
by Zacks Equity Research
ALTO, CSII, DELL, PRPL, and WRK have been added to the Zacks Rank #5 (Strong Sell) List on November 12, 2021
Cardiovascular Systems (CSII) Q1 Loss Wider Than Expected
by Zacks Equity Research
Cardiovascular Systems' (CSII) coronary franchise registers strong performance globally on continued strength in Japan and Europe.
Cardiovascular Systems (CSII) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -120.00% and -7.80%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Cardiovascular Systems (CSII) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.
DENTSPLY SIRONA (XRAY) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) third-quarter results are likely to reflect strong segmental performance.
Conformis (CFMS) to Post Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Conformis' (CFMS) third-quarter results are likely to reflect strength in core products.
PerkinElmer (PKI) to Post Q3 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) third-quarter results are likely to reflect strong performance at the Diagnostics segment.
McKesson (MCK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal second-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.
Cerner (CERN) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Cerner's (CERN) third-quarter results are likely to reflect gains from strategic deals.
Stryker (SYK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) third-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.
Baxter (BAX) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) third-quarter results are likely to reflect growth in its Acute Therapies business.
DexCom (DXCM) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.
What's in Store for West Pharmaceutical's (WST) Q3 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter results are likely to reflect strength in the Proprietary Products business.
What's in Store for Intuitive Surgical's (ISRG) Q3 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results are likely to reflect solid performance at the Instruments & Accessories segment.
Cardiovascular Systems (CSII) Treats 1st Patient With ViperCross
by Zacks Equity Research
Cardiovascular Systems' (CSII) ViperCross offers the correct balance of support and flexibility to navigate tortuous anatomy and cross challenging lesions.
Cardiovascular Systems (CSII) Down 6.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.